Here’s a Quick Way to Invest in the JSE’s Dividend Aristocrats


Sometimes it’s fun to pore over balance sheets and cash flow statements in search of that 10-bagger stock — the one that transforms your meager nest egg into a comfy cash cushion.

But let’s face it.

You usually have more enjoyable things to do on a weekday evening or Saturday afternoon.

That’s why exchange traded funds (ETFs) are one of the most useful tools in an investor’s toolkit.

Is KenolKobil Stock a Buy?


This is a guest contribution from Simon Maina. KenolKobil is a leading oil distributor and marketer of petroleum and other associated products (e.g. petrol stations) in East Africa. Of late, it has also extended its footprint into Southern Africa with Zambia being its most recent investment. I find shares of the company particularly attractive because […]

Here's Why Dangote Cement Is a Buy

Dangote Cement

When Africa’s richest man, Aliko Dangote, announced a 40% price cut on bags of Dangote Cement last week, Nigerian consumers rejoiced.

The stock market’s reaction, on the other hand, was decidedly less enthusiastic. Shares of the company have plunged nearly 19% since the news broke.

So, will the stock weigh down a portfolio’s performance going forward or does it have a solid foundation for market-beating gains? Let’s take a closer look.

What to Make of GSK Nigeria's Big Profit Drop

GSK Nigeria's most popular product

This week GSK Nigeria (GLAXOSMI) announced that its profits through the first nine months of 2014 dropped 23% compared to the same time period last year.

The news came as a bitter pill to investors. The stock has fallen nearly 16% over the past thirty days and now trades at its lowest price in 16 months.

Are the shares bad medicine? Just what the doctor ordered? Or something in between?

Let’s have a closer look at the numbers and see what they reveal.